top of page
Search

UK MHRA Guidance: The Northern Ireland MHRA Authorised Route (NIMAR)

The UK MHRA released this updated guidance today and added a section on 'Advertising and promotions' to Northern Ireland MHRA Authorised Route (NIMAR) guidance.

ree

This new route for supply became operational on 1 January 2022 after being approved by the Northern Ireland MHRA Authorised Route (NIMAR). The purpose of this supply route is to ensure that people in Northern Ireland (NI) can continue to access prescription-only medicines (POMs) in the event that authorized products cannot meet clinical needs.


Public health considerations make NIMAR an essential route for the supply of medicines and will be able to provide POMs to NI to meet the clinical need based on their marketing authorization for the GB.


NIMAR can only supply medicine to NI from GB if the following criteria are met:

  1. The product is classified as a Prescription Only Medicine (POM).

  2. The medicine that has a valid GB license thereby meets the MHRA’s stringent requirements for safety, quality, and efficacy.

  3. The medicine appears on the NIMAR list.

  4. Medicines that are unlicensed in GB and Pharmacy medicines and General Sales List medicines are not eligible for supply to NI via NIMAR.

Click this LINK to know more about the guidance on Northern Ireland MHRA Authorised Route.


Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page